A Phase 2 interventional study of Anifrolumab 300 mg and Anifrolumab 1000 mg in Systemic Lupus Erythematosus, sponsored by MedImmune LLC. Completed at 79 sites in 14 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-10-07.
Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic — 9 open to participants now, 11 under way, 6 of them phase 3. anifrolumab · Lupus Erythematosus, Systemic.
Among the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, this one is the 2nd largest by enrollment, is one of 2 that started in 2012, is one of 6 in phase 2, and was the 1st registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →9 of the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Australia, Belgium, Chile and 7 more countries
Ages 5–17
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 5–80
AstraZeneca · Sites in China
Ages 18–70
AstraZeneca · Sites in United States, Canada, France and 6 more countries
Ages 18–70
AstraZeneca · Sites in United States
Ages 18–130 · Women only
By country, each count listing its studies:
anifrolumab: first FDA approval 2021 (SAPHNELO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2012.
This study's enrollment of 626 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 159 across the 20 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 5 most frequent:
This study is registered under MedImmune LLC, one of the names counted as AstraZeneca. Under that name alone:
MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.
46 studies in Lupus Erythematosus, Systemic by AstraZeneca: 19 open now, 25 under way, 6 of them phase 3. Of 20 finished, 11 (55%) have results posted.
Among the 46 studies in Lupus Erythematosus, Systemic by AstraZeneca, this one is the 3rd largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2012, is one of 9 in phase 2, and was the 6th registered.
AstraZeneca’s Lupus Erythematosus, Systemic studies by the year they started, since 2008.
4 of the studies testing anifrolumab in Lupus Erythematosus, Systemic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05440422National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD | 2027-08-01 |
| NCT06594068AstraZenecaProspective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users | 2027-08-31 |
| NCT07913919University of CambridgeEffect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus Study | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, from their registry updates:
Among AstraZeneca’s 46 in Lupus Erythematosus, Systemic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of MEDI-546 compared to placebo in subjects with chronic, moderately-to-severely active systemic lupus erythematosus (SLE) with an inadequate response to standard of care treatment for SLE.
This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo controlled, parallel-group study to evaluate the efficacy and safety of 2 intravenous (IV) treatment regimens in adult participants with chronic, moderately-to-severely active SLE with an inadequate response to SOC SLE. The investigational product (anifrolumab or placebo) will be administered as a fixed dose every 4 weeks (28 days) for a total of 13 doses.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 300 milligram (mg) anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
Biological: Anifrolumab 300 mg
Participants will receive 1000 mg anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
Biological: Anifrolumab 1000 mg
Participants will receive placebo matched to anifrolumab intravenous (IV) infusion every 4 weeks for 48 weeks.
Other: Placebo
Participants will receive 300 milligram (mg) anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
Also known as: MEDI-546
Participants will receive 1000 mg anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
Also known as: MEDI-546
Participants will receive placebo matched to anifrolumab intravenous (IV) infusion every 4 weeks for 48 weeks.
Percentage of Participants Achieving an Systemic Lupus Erythematosus (SLE) Responder Index [SRI (4)] Response With Oral Corticosteroids (OCS) Tapering at Day 169
An SRI (4) responder defined as a participant who had 1) a reduction in baseline Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of greater than or equal to (\>=) 4 points; 2) no worsening of disease from baseline as measured by the Physician Global Assessment (MDGA) (worsening was defined as an increase of \>= 0.3 from baseline on a 0 to 3.0 visual analog scale); and 3) no new British Isles Lupus Assessment Group 2004 (BILAG-2004) Index 'A' organ system score and no more than one new or worsening BILAG-2004 Index 'B' organ system score. OCS tapering requires a sustained reduction of OCS from Day 85 through Day 169 \[less than 10 milligram per day (mg/day) and less or equal to the dose received on Day 1\]. SRI was analyzed by a logistic regression model.
Time frame: Day 169
Percentage of Type I Interferon (IFN) Test High Participants Achieving an Systemic Lupus Erythematosus Responder Index (SRI) (4) Response With Oral Corticosteroids (OCS) Tapering at Day 169
Type I IFN signature in whole blood assessed by using a 4-gene diagnostic test. The blood samples collected were to be used to prospectively identify participants as IFN test-high or test-low. The results of this test were used to stratify participants. An SRI (4) Responder was defined as a participant who had 1) a reduction in baseline SLEDAI-2K disease activity score of \>= 4 points; 2) no worsening of disease from baseline as measured by the Physician Global Assessment (MDGA) (worsening was defined as an increase of \>= 0.3 from baseline on a 0 to 3.0 visual analog scale); and 3) no new British Isles Lupus Assessment Group 2004 (BILAG-2004) Index A organ system score and no more than one new or worsening BILAG-2004 Index B organ system score. OCS tapering requires a sustained reduction of OCS from Day 85 through Day 169 \[less than 10 mg/day and less or equal to the dose received on Day 1\]. SRI was analyzed by a logistic regression model.
Time frame: Day 169
Percentage of Participants Achieving an Systemic Lupus Erythematosus (SLE) Responder Index [SRI (4)] Response With Oral Corticosteroids (OCS) Tapering at Day 365
An SRI (4) Responder was defined as a participant who had 1) a reduction in baseline SLEDAI-2K disease activity score of \>= 4 points; 2) no worsening of disease from baseline as measured by the MDGA (worsening was defined as an increase of \>= 0.3 from baseline on a 0 to 3.0 visual analog scale); and 3) no new British Isles Lupus Assessment Group 2004 (BILAG-2004) Index A organ system score and no more than one new or worsening BILAG-2004 Index B organ system score. OCS tapering requires a sustained reduction of OCS from Day 281 through Day 365 (less than 10 mg/day and less or equal to the dose received on Day 1). SRI was analyzed by a logistic regression model.
Time frame: Day 365
Percentage of Participants on Oral Corticosteroids (OCS) >=10 mg/Day of Prednisone or Equivalent at Baseline Who Were Able to Taper to Less Than or Equal to (<=) 7.5 mg/Day at Day 365
Participants on OCS \>=10 mg/day of prednisone or equivalent at baseline who were able to taper to \<= 7.5 mg/day at Day 365 were evaluated.
Time frame: Day 365
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESIs) and Treatment-Emergent Serious Adverse Events (TESAEs)
An adverse event (AE) was any untoward medical occurrence in a study participant administered a pharmaceutical product and which does not necessarily have a causal relationship with treatment. A serious AE (SAE) was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly (in offspring of participant). AEs may be treatment emergent (TE) \[that is, occurring after initial receipt of investigational product\] or non-TE. An AESI is one of scientific and medical concern specific to understanding biologics and requires close monitoring and rapid communication by investigator to sponsor.
Time frame: Day 1 (Baseline) to Day 422 (End of Study)
Number of Participants With Clinically Significant Laboratory Abnormalities in Investigations Reported as Treatment-Emergent Adverse Events
Any medically significant change in laboratory evaluations were recorded as Treatment emergent adverse events.
Time frame: Day 1 (Baseline) to Day 422 (End of Study)
Number of Participants With Vital Signs Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs)
Vital sign parameters are temperature, blood pressure, respiratory rate, heart rate and weight. Vital signs abnormalities were reported as TEAEs.
Time frame: Day 1 (Baseline) to Day 422 (End of Study)
Number of Participants With Electrocardiogram (ECG) Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs)
Any medically significant changes from the screening ECG was recorded as TEAEs. An abnormal ECG findings such as QT prolonged were reported as treatment emergent adverse events.
Time frame: Day 1 (Baseline) to Day 422 (End of Study)
Percentage of SLE Participants With Positive Anti-drug Antibody (ADA)
Anti-drug antibody responses to anifrolumab in serum were evaluated.
Time frame: Days 1, 85, 141, 169, 253, 337 (Treatment Phase), 365, 396, and 422 (Follow-up Period)
Neutralization Ratio of 21-Gene Type I Interferon (IFN) Signature for Participants With Positive Baseline Pharmacodynamic (PD) Gene Signature
The PD positive and negative gene signature was determined by comparing the expression of type I IFN-inducible genes in a 21-gene panel in study participants relative to pooled normal blood collected from healthy participants.
Time frame: Days 29, 85, 141, 169, 253, 337 (treatment phase), on Days 365, 396, and 422 (follow up period)
Maximum Observed Plasma Concentration (Cmax) of Anifrolumab at Day 1, 169 and 337
Maximum plasma concentration (Cmax) was defined as the peak plasma level of anifrolumab, derived from plasma concentration -time data.
Time frame: Pre-infusion and 15 minutes post-infusion on Day 1, 169 and 337
Accumulation Ratio of Maximum Observed Plasma Concentration (Cmax,AR) of Anifrolumab
Accumulation ratio for maximum plasma concentration (Cmax,AR) of anifrolumab after multiple administration at Day 169 and 337 was calculated.
Time frame: Pre-infusion and 15 minutes post-infusion on Day 169 and 337
Trough Concentration (Ctrough) of Anifrolumab at Day 29, 169 and 365
Trough concentration (Ctrough) of anifrolumab at Day 29, 169 and 365 were calculated.
Time frame: Pre-infusion and 15 minutes post-infusion on Day 29, 169 and 365
Accumulation Ratio of Trough Concentration (Ctrough,AR) of Anifrolumab at Day 169 and 365
Accumulation ratio for trough concentration (Ctrough,AR) of anifrolumab after multiple administration at Day 169 and 365 was calculated.
Time frame: Pre-infusion and 15 minutes post-infusion on Day 169 and 365
| Milestone | Placebo | Anifrolumab 300 mg | Anifrolumab 1000 mg |
|---|---|---|---|
| Started | 103 | 100 | 104 |
| Completed | 77 | 84 | 85 |
| Not completed | 26 | 16 | 19 |
| Withdrew: Lost to follow-up | 4 | 2 | 2 |
| Withdrew: Withdrawal by subject | 11 | 3 | 8 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Sponsor decision | 4 | 1 | 4 |
| Withdrew: Subject choice/subject moved | 2 | 1 | 1 |
| Withdrew: Investigator decision | 0 | 1 | 0 |
| Withdrew: Ae/saes | 2 | 1 | 1 |
| Withdrew: Received prohibited medication | 1 | 0 | 0 |
| Withdrew: Did not complete all 3 follow-up visits | 2 | 5 | 2 |
| Withdrew: Inadequate venous access | 0 | 2 | 0 |
An SRI (4) responder defined as a participant who had 1) a reduction in baseline Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of greater than or equal to (\>=) 4 points; 2) no worsening of disease from baseline as measured by the Physician Global Assessment (MDGA) (worsening was defined as an increase of \>= 0.3 from baseline on a 0 to 3.0 visual analog scale); and 3) no new British Isles Lupus Assessment Group 2004 (BILAG-2004) Index 'A' organ system score and no more than one new or worsening BILAG-2004 Index 'B' organ system score. OCS tapering requires a sustained reduction of OCS from Day 85 through Day 169 \[less than 10 milligram per day (mg/day) and less or equal to the dose received on Day 1\]. SRI was analyzed by a logistic regression model.
| Percentage of Participants | Placebo | Anifrolumab 300 mg | Anifrolumab 1000 mg |
|---|---|---|---|
| Percentage of Participants Achieving an Systemic Lupus Erythematosus (SLE) Responder Index [SRI (4)] Response With Oral Corticosteroids (OCS) Tapering at Day 169 | 17.6 | 34.3 | 28.8 |
Type I IFN signature in whole blood assessed by using a 4-gene diagnostic test. The blood samples collected were to be used to prospectively identify participants as IFN test-high or test-low. The results of this test were used to stratify participants. An SRI (4) Responder was defined as a participant who had 1) a reduction in baseline SLEDAI-2K disease activity score of \>= 4 points; 2) no worsening of disease from baseline as measured by the Physician Global Assessment (MDGA) (worsening was defined as an increase of \>= 0.3 from baseline on a 0 to 3.0 visual analog scale); and 3) no new British Isles Lupus Assessment Group 2004 (BILAG-2004) Index A organ system score and no more than one new or worsening BILAG-2004 Index B organ system score. OCS tapering requires a sustained reduction of OCS from Day 85 through Day 169 \[less than 10 mg/day and less or equal to the dose received on Day 1\]. SRI was analyzed by a logistic regression model.
| Percentage of Participants | Placebo | Anifrolumab 300 mg | Anifrolumab 1000 mg |
|---|---|---|---|
| Percentage of Type I Interferon (IFN) Test High Participants Achieving an Systemic Lupus Erythematosus Responder Index (SRI) (4) Response With Oral Corticosteroids (OCS) Tapering at Day 169 | 13.2 | 36 | 28.2 |
An SRI (4) Responder was defined as a participant who had 1) a reduction in baseline SLEDAI-2K disease activity score of \>= 4 points; 2) no worsening of disease from baseline as measured by the MDGA (worsening was defined as an increase of \>= 0.3 from baseline on a 0 to 3.0 visual analog scale); and 3) no new British Isles Lupus Assessment Group 2004 (BILAG-2004) Index A organ system score and no more than one new or worsening BILAG-2004 Index B organ system score. OCS tapering requires a sustained reduction of OCS from Day 281 through Day 365 (less than 10 mg/day and less or equal to the dose received on Day 1). SRI was analyzed by a logistic regression model.
| Percentage of Participants | Placebo | Anifrolumab 300 mg | Anifrolumab 1000 mg |
|---|---|---|---|
| Percentage of Participants Achieving an Systemic Lupus Erythematosus (SLE) Responder Index [SRI (4)] Response With Oral Corticosteroids (OCS) Tapering at Day 365 | 25.5 | 51.5 | 38.5 |
Participants on OCS \>=10 mg/day of prednisone or equivalent at baseline who were able to taper to \<= 7.5 mg/day at Day 365 were evaluated.
| Percentage of Participants | Placebo | Anifrolumab 300 mg | Anifrolumab 1000 mg |
|---|---|---|---|
| Percentage of Participants on Oral Corticosteroids (OCS) >=10 mg/Day of Prednisone or Equivalent at Baseline Who Were Able to Taper to Less Than or Equal to (<=) 7.5 mg/Day at Day 365 | 26.6 | 56.4 | 31.7 |
An adverse event (AE) was any untoward medical occurrence in a study participant administered a pharmaceutical product and which does not necessarily have a causal relationship with treatment. A serious AE (SAE) was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly (in offspring of participant). AEs may be treatment emergent (TE) \[that is, occurring after initial receipt of investigational product\] or non-TE. An AESI is one of scientific and medical concern specific to understanding biologics and requires close monitoring and rapid communication by investigator to sponsor.
| Participants | Placebo | Anifrolumab 300 mg | Anifrolumab 1000 mg |
|---|---|---|---|
| TEAEs | 78 | 84 | 90 |
| TESAEs | 19 | 16 | 18 |
| AESIs | 12 | 10 | 15 |
Any medically significant change in laboratory evaluations were recorded as Treatment emergent adverse events.
| Participants | Placebo | Anifrolumab 300 mg | Anifrolumab 1000 mg |
|---|---|---|---|
| Neutrophil count increased | 0 | 1 | 3 |
| Leukocytosis | 0 | 1 | 2 |
| Leukopenia | 2 | 0 | 3 |
| Neutropenia | 0 | 0 | 3 |
| Anaemia | 0 | 0 | 2 |
| Iron deficiency anaemia | 0 | 1 | 1 |
| Lymphopenia | 0 | 0 | 2 |
| Microcytic anaemia | 1 | 0 | 2 |
| Thrombocytosis | 0 | 1 | 0 |
| White blood cell count increased | 0 | 0 | 1 |
| Monocyte count increased | 0 | 0 | 1 |
| Hypochromic anaemia | 1 | 0 | 0 |
| Hyperglycaemia | 1 | 3 | 1 |
| Hypokalaemia | 2 | 3 | 0 |
| Hepatic enzyme increased | 1 | 0 | 3 |
| Hypocalcaemia | 0 | 1 | 1 |
| Lipid metabolism disorder | 0 | 1 | 1 |
| Alanine aminotransferase increased | 0 | 1 | 1 |
| Aspartate aminotransferase increased | 0 | 2 | 0 |
| Blood creatine phosphokinase increased | 0 | 1 | 1 |
| Hyperlipidaemia | 1 | 0 | 1 |
| Hypertriglyceridaemia | 2 | 1 | 0 |
| Hyponatraemia | 0 | 0 | 1 |
| Blood alkaline phosphatase increased | 0 | 1 | 0 |
| Gamma-glutamyltransferase increased | 0 | 1 | 0 |
| Glomerular filtration rate decreased | 0 | 1 | 0 |
| Transaminases increased | 1 | 0 | 1 |
| Dyslipidaemia | 1 | 0 | 0 |
| Alanine aminotransferase abnormal | 1 | 0 | 0 |
| Aspartate aminotransferase abnormal | 1 | 0 | 0 |
| Blood triglycerides abnormal | 1 | 0 | 0 |
| Glomerular filtration rate increased | 1 | 0 | 0 |
Vital sign parameters are temperature, blood pressure, respiratory rate, heart rate and weight. Vital signs abnormalities were reported as TEAEs.
| Participants | Placebo | Anifrolumab 300 mg | Anifrolumab 1000 mg |
|---|---|---|---|
| Hypertension | 7 | 3 | 2 |
| Pyrexia | 5 | 0 | 3 |
| Blood pressure increased | 0 | 2 | 1 |
| Blood pressure decreased | 0 | 0 | 1 |
| Hypotension | 0 | 1 | 0 |
| Secondary hypertension | 0 | 0 | 1 |
| Weight increased | 0 | 0 | 1 |
| Blood pressure abnormal | 1 | 0 | 0 |
| Chills | 1 | 0 | 0 |
| Hypertensive emergency | 1 | 0 | 0 |
Any medically significant changes from the screening ECG was recorded as TEAEs. An abnormal ECG findings such as QT prolonged were reported as treatment emergent adverse events.
| Participants | Placebo | Anifrolumab 300 mg | Anifrolumab 1000 mg |
|---|---|---|---|
| Number of Participants With Electrocardiogram (ECG) Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs) | 0 | 0 | 2 |
Anti-drug antibody responses to anifrolumab in serum were evaluated.
| Percentage of Participants | Placebo | Anifrolumab 300 mg | Anifrolumab 1000 mg |
|---|---|---|---|
| Day 1 (n=100,98,105) | 1.0 | 1.0 | 1.9 |
| Day 85 (n=91,93,98) | 1.1 | 0.0 | 0.0 |
| Day 141 (n=84,94,93) | 2.4 | 0.0 | 2.2 |
| Day 169 (n=81,89,92) | 2.5 | 0.0 | 1.1 |
| Day 253 (n=72,86,86) | 0.0 | 1.2 | 0.0 |
| Day 337 (n=70,87,76) | 0.0 | 1.1 | 0.0 |
| Day 365 (n=85,96,94) | 0.0 | 1.0 | 1.1 |
| Day 396 (n=78,88,90) | 0.0 | 2.3 | 0.0 |
| Day 422 (n=76,86,77) | 1.3 | 5.8 | 0.0 |
| Any Visit Post Baseline (n= 99,98,102) | 3.0 | 5.1 | 2.0 |
The PD positive and negative gene signature was determined by comparing the expression of type I IFN-inducible genes in a 21-gene panel in study participants relative to pooled normal blood collected from healthy participants.
| Ratio | Placebo | Anifrolumab 300 mg | Anifrolumab 1000 mg |
|---|---|---|---|
| Day 29 (n= 68, 66, 73) | -0.753 ± 44.678 | 70.194 ± 40.028 | 82.056 ± 16.108 |
| Day 85 (n= 63, 62, 72) | -5.412 ± 44.354 | 72.639 ± 34.443 | 79.350 ± 40.428 |
| Day 141 (n= 59, 64, 68) | -25.411 ± 78.391 | 73.662 ± 36.684 | 88.569 ± 10.364 |
| Day 169 (n= 56, 60, 66) | -17.122 ± 67.603 | 77.364 ± 30.733 | 88.126 ± 10.278 |
| Day 253 (n= 50, 60, 61) | -9.908 ± 49.826 | 73.972 ± 41.267 | 86.099 ± 15.615 |
| Day 337 (n= 49, 59, 53) | -13.784 ± 45.541 | 79.363 ± 28.803 | 87.811 ± 8.410 |
| Day 365 (n= 58, 66, 68) | -6.428 ± 50.358 | 72.796 ± 35.552 | 81.115 ± 53.121 |
| Day 396 (n= 56, 61, 64) | -22.106 ± 64.529 | 11.510 ± 56.385 | 72.291 ± 31.182 |
| Day 422 (n= 53, 57, 55) | -31.777 ± 70.173 | -0.836 ± 44.596 | 37.532 ± 66.339 |
Maximum plasma concentration (Cmax) was defined as the peak plasma level of anifrolumab, derived from plasma concentration -time data.
| micrograms/milliliter (mcg/mL) | Anifrolumab 300 mg | Anifrolumab 1000 mg |
|---|---|---|
| Day 1 (n=98,104) | 82.8 ± 64.5 | 248 ± 79.9 |
| Day 169 (n=86,87) | 110 ± 63.7 | 375 ± 137 |
| Day 337 (n=83,67) | 127 ± 64.6 | 439 ± 140 |
Accumulation ratio for maximum plasma concentration (Cmax,AR) of anifrolumab after multiple administration at Day 169 and 337 was calculated.
| Ratio | Anifrolumab 300 mg | Anifrolumab 1000 mg |
|---|---|---|
| Day 169 (n=81,86) | 1.36 ± 63.7 | 1.43 ± 137 |
| Day 337 (n=78,66) | 1.56 ± 64.6 | 1.76 ± 140 |
Trough concentration (Ctrough) of anifrolumab at Day 29, 169 and 365 were calculated.
| microgram per milliliter | Anifrolumab 300 mg | Anifrolumab 1000 mg |
|---|---|---|
| Day 29 (n=95,99) | 7.95 ± 6.17 | 46.8 ± 24.6 |
| Day 169 (n=87,87) | 18.4 ± 12.9 | 110 ± 60.5 |
| Day 365 (n=83,71) | 23.6 ± 15.5 | 154 ± 89.2 |
Accumulation ratio for trough concentration (Ctrough,AR) of anifrolumab after multiple administration at Day 169 and 365 was calculated.
| Ratio | Anifrolumab 300 mg | Anifrolumab 1000 mg |
|---|---|---|
| Day 169 (n=82,86) | 2.49 ± 63.7 | 2.29 ± 137 |
| Day 365 (n=79,70) | 3.06 ± 64.6 | 3.02 ± 140 |
Collected over Day 1 (Baseline) to Day 422 (End of Study). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 19/101 (18.8%) | 36/101 (35.6%) |
| Anifrolumab 300 mg | — | 16/99 (16.2%) | 40/99 (40.4%) |
| Anifrolumab 1000 mg | — | 18/105 (17.1%) | 46/105 (43.8%) |
| Event | Placebo | Anifrolumab 300 mg | Anifrolumab 1000 mg |
|---|---|---|---|
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 6/101 | 3/99 | 3/105 |
| Chest painGeneral disorders | 1/101 | 0/99 | 3/105 |
| InfluenzaInfections and infestations | 0/101 | 2/99 | 1/105 |
| PneumoniaInfections and infestations | 2/101 | 2/99 | 2/105 |
| Ischaemic strokeNervous system disorders | 2/101 | 0/99 | 0/105 |
| VasculitisVascular disorders | 2/101 | 0/99 | 0/105 |
| HeadacheNervous system disorders | 1/101 | 0/99 | 2/105 |
| GoitreEndocrine disorders | 0/101 | 1/99 | 0/105 |
| Retinal disorderEye disorders | 0/101 | 1/99 | 0/105 |
| Abdominal painGastrointestinal disorders | 0/101 | 1/99 | 0/105 |
| Event | Placebo | Anifrolumab 300 mg | Anifrolumab 1000 mg |
|---|---|---|---|
| Urinary tract infectionInfections and infestations | 11/101 | 15/99 | 7/105 |
| HeadacheNervous system disorders | 13/101 | 12/99 | 12/105 |
| NasopharyngitisInfections and infestations | 4/101 | 12/99 | 12/105 |
| Upper respiratory tract infectionInfections and infestations | 10/101 | 12/99 | 11/105 |
| BronchitisInfections and infestations | 4/101 | 7/99 | 9/105 |
| DiarrhoeaGastrointestinal disorders | 4/101 | 4/99 | 8/105 |
Intent-to-treat (ITT) population included all participants who were randomized into the study.
| Age, Continuous(Years) | Placebo | Anifrolumab 300 mg | Anifrolumab 1000 mg | Total |
|---|---|---|---|---|
| Mean | 39.2 ± 12.9 | 39.3 ± 12.0 | 40.8 ± 11.6 | 39.8 ± 12.2 |
| Sex: Female, Male(Participants) | Placebo | Anifrolumab 300 mg | Anifrolumab 1000 mg | Total |
|---|---|---|---|---|
| Female | 94 | 94 | 99 | 287 |
| Male | 9 | 6 | 5 | 20 |
| Race/Ethnicity, Customized(Participants) | Placebo | Anifrolumab 300 mg | Anifrolumab 1000 mg | Total |
|---|---|---|---|---|
| American Indian or Alaskan Native | 0 | 4 | 1 | 5 |
| Asian | 13 | 3 | 6 | 22 |
| Black or African American | 12 | 19 | 10 | 41 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| White | 41 | 36 | 51 | 128 |
| Other | 36 | 37 | 36 | 109 |
| Multiple category checked | 1 | 1 | 0 | 2 |
| Region of Enrollment(Participants) | Placebo | Anifrolumab 300 mg | Anifrolumab 1000 mg | Total |
|---|---|---|---|---|
| BRAZIL | 3 | 0 | 0 | 3 |
| BULGARIA | 3 | 2 | 4 | 9 |
| COLOMBIA | 16 | 10 | 18 | 44 |
| CZECH REPUBLIC | 1 | 0 | 2 | 3 |
| HUNGARY | 2 | 5 | 3 | 10 |
| INDIA | 2 | 1 | 0 | 3 |
| MEXICO | 4 | 7 | 5 | 16 |
| PERU | 15 | 22 | 13 | 50 |
| POLAND | 11 | 9 | 12 | 32 |
| ROMANIA | 1 | 0 | 1 | 2 |
| SOUTH KOREA | 3 | 0 | 3 | 6 |
| TAIWAN | 7 | 2 | 3 | 12 |
| UKRAINE | 7 | 4 | 11 | 22 |
| UNITED STATES OF AMERICA | 28 | 38 | 29 | 95 |
| Baseline weight(kilogram) | Placebo | Anifrolumab 300 mg | Anifrolumab 1000 mg | Total |
|---|---|---|---|---|
| Mean | 68.08 ± 18.98 | 69.62 ± 17.09 | 70.74 ± 17.29 | 69.48 ± 17.79 |
The record gives a start of Jan 2012, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anifrolumab
Lupus Erythematosus, Systemic →